888-838-0432

Please note: you must be a healthcare professional to order this test.

buy_now_button

Improve patient care with early ID of cognitive impairment
Easily administered by any healthcare professional on staff
Monitor patients’ cognitive health over time
Reimbursed up to $120 per test (several CPT codes)
Can be incorporated into Annual Wellness Visits
Results are easily loaded into EMR system
A better way to test and track cognitive function
Verbal Fluency
Visual-Spatial
Access via secure internet log-in
Easily create and manage accounts
Test takes approximately 6-8 minutes
Integrates easily into fast-paced workflows
Minimal training required (available online)
Get started immediately
Affordably priced
Using ALZselftest is easy and afordable
Physician Results
Early AD is characterized by neurocognitive deficits in two or
more cognitive domains. Early AD typically involves impairment
in several domains, with memory being the most likely to show
significant deficits. Repeating oneself and asking the same
question over again is frequently one of the earliest signs of
Alzheimer’s disease.
Another area of concern is an individual’s reaction to a negative report of memory problems
or other cognitive symptoms. In our database, however, 48% of the Early AD group manifests
symptoms of anosognosia (unawareness) of memory or other cognitive deficits. In Early AD,
activities of daily living may or may not be compromised, and frequently objective
confirmation of the clinical history may be necessary. In this stage, the clinical examination
and neuroimaging data are often critical in confirming the diagnosis.
Difficulty in traveling to a new location and decreased
organizational capacity are early symptoms, as well as difficulty
in paying bills, writing checks and balancing the checkbook.
Medications are very important at this stage of impairment, and
further monitoring is vital to the overall care and quality of life
for the patient.
CST MEAN SCORE:
25
STANDARD DEVIATION
3.20, MINIMUM 22,
MAXIMUM 27
(2) EARLY ALZHEIMER’S DISEASE (EAD):
Patient Results
The ALZselftest™, also known as Computerized Self Test™ (CST), from Medinteract is an
effective, rapid-assessment tool used by physicians for early identification of cognitive
impairment in patients. The ALZselftest™ (CST) helps physicians zero in on early signs of
dementia and AD, which can help patients receive treatment much earlier in the disease process when treatment options are
most effective. Designed by a physician, the solution integrates easily into the fast-paced workflow of busy medical practices.
97% accurate in determining whether someone is normal or cognitively impaired
95% accurate in specifying the severity of cognitive impairment
Early screening tool for Alzheimer’s Disease and dementia
A web-based diagnostic screening tool that measures six cognitive domaines
“In conclusion, the CST demonstrates a high degree of sensitivity
and specificity and is capable of
accurately identifying cognitive
impairment in patients with
variable degrees of cognitive
abnormality.”
Journal of Alzheimer’s Disease
April, 2010
Call: 877-ALZ-SELF (259-7353) ext. 3
email: info@alzselftest.com
visit: www.medinteract.com
How to Get Started
The Computerized Self Test (CST) is available to your practice
through a monthly subscription or on a per-test basis.
Contact us for a free trial.
Early detection of cognitive impairment is the first step in the fight against dementia and AD

Menu